Evidence map›Paper›PMID 35772419›Full record

ArticleJournal of psychopharmacology (Oxford, England)2022

The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls.

Will Lawn, Claire Mokrysz, Rachel Lees, Katie Trinci, Kat Petrilli, Martine Skumlien, Anna Borissova, Shelan Ofori, Catherine Bird, Grace Jones and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Assessing Cannabis Use in People with Psychosis.Cannabis and cannabinoid research · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Will LawnDepartment of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-0143-2724
Claire MokryszClinical Psychopharmacology Unit, University College London, London, UK.
Rachel LeesAddiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Katie TrinciClinical Psychopharmacology Unit, University College London, London, UK.
Kat PetrilliAddiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Martine SkumlienDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Anna BorissovaDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Shelan OforiClinical Psychopharmacology Unit, University College London, London, UK.
Catherine BirdCentre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Grace JonesClinical Psychopharmacology Unit, University College London, London, UK.
Michael Ap BloomfieldClinical Psychopharmacology Unit, University College London, London, UK.ORCID 0000-0002-1972-4610
Ravi K DasClinical Psychopharmacology Unit, University College London, London, UK.
Matthew B WallClinical Psychopharmacology Unit, University College London, London, UK.
Tom P FreemanClinical Psychopharmacology Unit, University College London, London, UK.
H Valerie CurranClinical Psychopharmacology Unit, University College London, London, UK.
University College London · GBKing's College London · GBUniversity College Hospital · GBUniversity of Bath · GBInvicro (United Kingdom) · GBUniversity of Cambridge · GB

Funding

Department of HealthMedical Research Council MR/P012728/1
6 · The paper itself

Abstract

backgroundAdolescence is characterised by psychological and neural development. Cannabis harms may be accentuated during adolescence. We hypothesised that adolescents would be more vulnerable to the associations between cannabis use and mental health and addiction problems than adults.

methodAs part of the 'CannTeen' study, we conducted a cross-sectional analysis. There were 274 participants: split into groups of adolescent users (

resultsAfter adjustment for covariates, adolescent users were more likely to have severe CUD than adult users (odd ratio = 3.474, 95% confidence interval (CI) = 1.501-8.036). Users reported greater psychotic-like symptoms than controls (

conclusionAdolescent cannabis users are more likely than adult cannabis users to have severe CUD. Adolescent cannabis users have greater psychotic-like symptoms than adult cannabis users and adolescent controls, through an additive effect. There was no evidence of an amplified vulnerability to cannabis-related increases in subclinical depression, anxiety or psychotic-like symptoms in adolescence. However, poorer mental health was associated with the presence of severe CUD.

Indexed as

AnxietyDepressionMarijuana AbusePsychotic DisordersAdolescentAdultCase-Control StudiesCross-Sectional StudiesHumansaddictionadolescenceanxietyCannabiscannabis use disorderdepressionmarijuanapsychotic-like symptoms

Identifiers

PMID35772419
PMCPMC9716489
OpenAlexW4283750731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.